Fresno, Calif. – January 23, 2025 – Tamarack Biotics announced the filing of a 403(h) Notification to gain US FDA approval for the company’s UV treatment as an alternative to heat for pasteurizing milk. The FDA has 120 days in which to respond to the Notification. After several false starts, Tamarack and the FDA jointly developed an approval plan that Tamarack has now completed. Extensive experimentation demonstrated that Tamarack’s UV treatment eliminates all pathogens, likely to be found in milk, far more effectively than heat.
“Tamarack’s TruActive® products utilize proprietary UV treatment and low temperature drying to retain more of raw milk’s immune active proteins and enzymes than any other product available today,” said Bob Comstock, Chief Executive Officer of Tamarack Biotics. “These immune active proteins offer health benefits to everyone, but particularly young children, sports enthusiasts, and the elderly.”
A University of California Davis-led clinical trial proved that TruActive® restored immune function in an elderly population. Raw milk proteins positively impact gut health, and the non-denatured proteins have significantly higher bioavailability. Additionally, the taste, smell, and dissolution are far superior to existing thermally pasteurized products.
Tamarack has also started a mouse-model allergy prevention clinical trial which will evaluate TruActive®’s ability to reduce asthma and food allergy development in children. Additionally, multiple European Commission funded allergy studies demonstrated that children who consume raw milk early in life suffer vastly fewer allergies. Researchers believe bioactive proteins provide this protective effect, and TruActive® retains these same proteins.
Leave a Reply